Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 766 to 780 of 1128 results for criteria

  1. Major trauma: assessment and initial management (NG39)

    This guideline covers the rapid identification and early management of major trauma in pre-hospital and hospital settings, including ambulance services, emergency departments, major trauma centres and trauma units. It aims to reduce deaths and disabilities in people with serious injuries by improving the quality of their immediate care. It does not cover care for people with burns.

  2. New age-based blood test thresholds recommended by NICE will help GPs catch ovarian cancer earlier

    More women with ovarian cancer could be diagnosed earlier under proposed new NICE guidance that replaces a one-size-fits-all blood test threshold with personalised, age-based criteria.

  3. Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (HTG292)

    Evidence-based recommendations on 3 electroencephalography (EEG)-based depth of anaesthesia monitors for assessing a patient’s response to anaesthetic drugs during surgery. The monitors are Bispectral Index (BIS), E-Entrophy and Narcotrend-Compact M.

  4. Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over (HST33)

    Evidence-based recommendations on leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over.

  5. Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)

    Evidence-based recommendations on selective internal radiation therapies SIR-Spheres (Sirtex), TheraSphere (BTG) and QuiremSphere (Quirem Medical) for treating hepatocellular carcinoma in adults.

  6. Axonics sacral neuromodulation system for treating refractory overactive bladder (HTG554)

    Evidence-based recommendations on Axonics sacral neuromodulation system for treating refractory overactive bladder.

  7. Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (HTG545)

    Evidence-based recommendations on Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia.

  8. BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume (MIB50)

    NICE has developed a medtech innovation briefing (MIB) on the BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume

  9. Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis (HTG441)

    Evidence-based recommendations on multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis.

  10. Blood transfusion (NG24)

    This guideline covers the assessment for and management of blood transfusions in adults, young people and children over 1 year old. It covers the general principles of blood transfusion, but does not make recommendations relating to specific conditions.

  11. Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (TA429)

    Evidence-based recommendations on ibrutinib (Imbruvica) for treating chronic lymphocytic leukaemia in adults.

  12. Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)

    Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.

  13. Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted (TA864)

    Evidence-based recommendations on nintedanib (Ofev) for treating idiopathic pulmonary fibrosis in adults when forced vital capacity is above 80% predicted.

  14. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (TA210)

    Evidence-based recommendations on clopidogrel and modified-release dipyridamole for preventing occlusive vascular events in adults.